First-ever AI-designed vaccine reaches human trials

This experimental approach seeks to establish immunity against a broad range of viruses, including all known coronaviruses, rather than targeting a single circulating strain. Traditional vaccine development typically relies on a currently circulating viral strain. However, certain viruses are adept at mutating, causing conventional vaccines to lose efficacy quickly. This is why seasonal flu and Covid shots require regular updates. “We’re always behind,” Professor Jonathan Heeney of Cambridge told the BBC, noting his team’s goal is to reverse this dynamic. “What we’re trying to do is get ahead of the curve.” The researchers claim it is the first time a vaccine’s key component has been designed entirely by AI and then trialled in people. To achieve this, researchers compiled genetic codes — the biological instruction manuals — from coronaviruses documented by global surveillance programs. An AI system analysed these sequences to design a “super-antigen.” Antigens are essential components of vaccines that train the immune system to attack foreign invaders. This super-antigen trains the immune system to defend against the entire family of viruses, providing immunity even if viruses mutate or a new infection jumps from animals to humans. The technology is “surprising all of us”, Heeney said, adding it is “amazing what we can do with it for the good of humanity”. “This is about making vaccines that protect us, not just from today’s viruse